<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024193</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-NB-1999-02</org_study_id>
    <secondary_id>CDR0000068899</secondary_id>
    <secondary_id>SFOP-NB97</secondary_id>
    <secondary_id>EU-20106</secondary_id>
    <nct_id>NCT00024193</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma</brief_title>
  <official_title>A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Societe Francaise Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give&#xD;
      higher doses of chemotherapy drugs to kill more tumor cells. Chemotherapy, given before and&#xD;
      after surgery, followed by peripheral stem cell transplantation may be an effective treatment&#xD;
      for metastatic neuroblastoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy, given before and after&#xD;
      surgery, followed by peripheral stem cell transplantation in treating patients who have&#xD;
      metastatic neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of induction chemotherapy followed by surgical resection and&#xD;
           consolidation chemotherapy with autologous peripheral blood stem cell transplantation in&#xD;
           patients with metastatic neuroblastoma.&#xD;
&#xD;
        -  Determine the tolerability and feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Determine the medium and long-term results in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive induction chemotherapy comprising cyclophosphamide IV over 6 hours on days 1&#xD;
      and 2 and doxorubicin IV continuously and vincristine IV continuously over days 1-3 of&#xD;
      courses 1, 2, 4, and 6. Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide&#xD;
      IV over 2 hours on days 1-3 of induction courses 3, 5, and 7. Patients also receive&#xD;
      filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 5 of courses 3, 5, and 7&#xD;
      and continuing until blood counts recover. Treatment repeats every 21 days.&#xD;
&#xD;
      At the completion of induction chemotherapy, patients undergo surgical resection. Patients in&#xD;
      complete remission receive high-dose consolidation chemotherapy comprising oral busulfan&#xD;
      every 6 hours on days -7 to -3 and melphalan IV over 2 minutes on day -2. Autologous&#xD;
      peripheral blood stem cells (PBSC) are reinfused on day 0. Patients with n-myc tumor&#xD;
      amplification undergo radiotherapy at least 70 days after PBSC transplantation.&#xD;
&#xD;
      Patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15-45 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed primary neuroblastoma OR&#xD;
&#xD;
          -  Presence of neuroblasts in bone marrow associated with an elevation of urinary&#xD;
             catecholamines&#xD;
&#xD;
          -  Metastatic disease demonstrated by at least 1 of the following:&#xD;
&#xD;
               -  Medullary invasion (bone marrow involvement) as indicated by bone uptake on&#xD;
                  meta-iodobenzyl guanidine I 123 or bone lesions on bone scan&#xD;
&#xD;
               -  Distant metastases to liver, pleura, lungs, or distant nodes&#xD;
&#xD;
          -  No 11-22 translocation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  1 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No contraindications to study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice A. Kohler, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D. Valteau-Couanet</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

